Scott Burrows

Scott Burrows serves as the Chief Financial Officer at Spyre Therapeutics since 2023 and previously held the same position at Arcutis Biotherapeutics, Inc. from 2019 to 2023. Prior experience includes Vice President of Investor Relations at Shire from 2018 to 2019 before its acquisition by Takeda, and a progression of roles at Amgen from 2003 to 2018, culminating in Investor Relations Director. Burrows has a strong background in corporate financial planning and analysis, treasury management, and revenue forecasting, with earlier experience as a Senior Consultant at Arthur Andersen LLP. Academic qualifications include an M.B.A. from UCLA Anderson School of Management and a B.A. in Business Economics with a minor in Accounting from UCLA.